Science News Today
  • Biology
  • Physics
  • Chemistry
  • Astronomy
  • Health and Medicine
  • Psychology
  • Earth Sciences
  • Archaeology
  • Technology
Science News Today
  • Biology
  • Physics
  • Chemistry
  • Astronomy
  • Health and Medicine
  • Psychology
  • Earth Sciences
  • Archaeology
  • Technology
No Result
View All Result
Science News Today
No Result
View All Result
Home Health and Medicine

Scientists Discover How T Cell Memory Influences CAR-T Cell Effectiveness

by Muhammad Tuhin
January 3, 2025
Antigen experience history directs multiple aspects of in vitro function of mouse CAR8 T cells. Credit: Nature Immunology (2025). DOI: 10.1038/s41590-024-02034-1

Antigen experience history directs multiple aspects of in vitro function of mouse CAR8 T cells. Credit: Nature Immunology (2025). DOI: 10.1038/s41590-024-02034-1

0
SHARES

Researchers at the University of Colorado Anschutz Medical Campus have made a significant discovery that could improve the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy, a promising immunotherapy for various cancers. This breakthrough focuses on the phenomenon of “memory” within CAR-T cells, showing that some of these cells carry the memory of previous encounters with pathogens such as bacteria, viruses, and other antigens. This finding could allow scientists to develop more targeted and precise CAR-T cell therapies, potentially enhancing the treatment’s effectiveness and reducing side effects.

You might also like

Your Brain Keeps Growing New Neurons Even in Old Age

This Pig Kidney Survived in a Human Body for 61 Days and Changed Everything

One Hormone Combo Raises Cancer Risk While Another May Lower It

CAR-T therapy involves modifying a patient’s T cells—key immune cells that fight infections and cancer—so that they can specifically target and attack cancer cells. The process begins with extracting T cells from the patient’s blood, then engineering them in the laboratory to express a chimeric antigen receptor (CAR), which enables the cells to recognize cancer cells. These modified T cells are then infused back into the patient, where they can seek out and destroy cancer cells. CAR-T therapies have shown remarkable success, particularly in treating leukemia and lymphoma, and have been used to treat patients who have not responded to other treatments.

While CAR-T therapy has been groundbreaking, scientists have long known that there is variability in the effectiveness of CAR-T cells between patients. However, the reasons behind this variability have remained poorly understood. This study, published in Nature Immunology, sheds light on a crucial factor: the memory of past antigen encounters within the CAR-T cells themselves. The research revealed that, even after undergoing extensive manufacturing processes to insert the CAR into the T cells, some of these engineered cells carried “memory” of prior interactions with antigens.

This memory appears to be imprinted onto the cells in such a way that those with prior antigen exposure behave differently from those that have never encountered an antigen. These “memory cells” are able to kill cancer cells more rapidly, but they become exhausted more quickly and reproduce more slowly. This could open the door to potential cancer relapse, as exhausted T cells may be less effective at sustaining a prolonged anti-cancer response.

In contrast, the study also uncovered the advantages of “naïve” cells, which have never encountered an antigen. While naïve T cells lacked the disease-fighting imprinting of memory cells, they exhibited more favorable disease-fighting capabilities. The researchers found that naïve cells were more robust in their expansion and were less prone to exhaustion compared to memory cells. These findings were particularly notable as they suggested that naïve cells could be manipulated to perform better in the context of cancer treatment.

The research team, led by Terry Fry, MD, professor of pediatrics, oncology, and hematology at the University of Colorado School of Medicine, and Kole DeGolier, Ph.D., an immunology researcher, identified specific gene targets that could be used to modulate the behavior of both memory and naïve CAR-T cells to enhance their function. One of the most promising gene targets identified was RUNX2, a gene that appears to play a crucial role in boosting the performance of naïve T cells. When RUNX2 was introduced into naïve cells, they not only lived longer but also reproduced more quickly, making them more effective at fighting cancer. These results suggested that manipulating RUNX2 could provide a way to optimize CAR-T cell function, making them more durable and less susceptible to exhaustion.

To verify their findings, the researchers conducted experiments first using mouse models and then with human T cells. They found that T cells from vaccinated individuals—those who had been previously exposed to antigens—changed after encountering the vaccine antigens in the lymph nodes. These cells exhibited the characteristic “memory” response, quickly and effectively targeting leukemia cells. However, they also experienced faster exhaustion compared to naïve T cells, highlighting the trade-off between rapid effectiveness and long-term durability.

The study also showed that by manipulating the RUNX2 gene in naïve T cells, they could overcome some of the limitations associated with memory cells. The modified naïve T cells showed better cancer-killing abilities, with a longer lifespan and increased resistance to exhaustion. These findings suggest that enhancing the function of naïve cells through genetic manipulation could result in more effective CAR-T therapies, potentially offering a solution to one of the major challenges of cancer immunotherapy.

The discovery of these epigenetic differences between memory and naïve CAR-T cells opens up new avenues for research into how to optimize the use of CAR-T therapies. By targeting specific genes like RUNX2, scientists may be able to develop methods to modify CAR-T cells in ways that improve their anti-cancer capabilities while minimizing side effects such as the severe inflammatory responses that are sometimes triggered by the therapy.

The potential applications of these findings are significant. In particular, researchers believe that manipulating CAR-T cells to enhance the longevity and effectiveness of naïve cells could lead to more durable and long-lasting responses in patients. This could be especially beneficial for patients with solid tumors, where T cell exhaustion has been a major barrier to effective treatment. Exhaustion is a state where T cells become less effective over time, rendering them unable to mount a sustained attack against the tumor. The research suggests that by manipulating certain genes, including RUNX2, it may be possible to prevent or delay exhaustion, thereby enhancing the ability of CAR-T cells to fight solid tumors.

Additionally, this study could help address the variability in CAR-T cell therapy outcomes. By better understanding how the prior history of a T cell influences its performance, researchers can begin to develop more personalized therapies. For example, scientists could engineer CAR-T cells with specific modifications to suit individual patient needs, improving the likelihood of a successful response.

The study also underscores the importance of further exploration into the role of epigenetics—the chemical changes that regulate gene expression—in shaping the behavior of CAR-T cells. The findings suggest that epigenetic modifications could be leveraged to create CAR-T therapies that are more finely tuned and optimized for specific patient populations and cancer types.

The implications of this research extend beyond the realm of CAR-T therapy. It may also pave the way for broader applications in immunotherapy, where understanding the cellular history and memory of immune cells could lead to more effective treatments for a range of diseases, including autoimmune disorders, infections, and potentially even aging-related conditions. By harnessing the memory and adaptability of immune cells, scientists could develop therapies that are not only more effective but also safer, with fewer side effects.

The study also opens up exciting possibilities for combining CAR-T therapy with other immunotherapeutic strategies. For instance, combining the targeted manipulation of genes like RUNX2 with checkpoint inhibitors or other immune-boosting treatments could create powerful combination therapies that enhance the immune system’s ability to recognize and destroy cancer cells. This approach could help overcome some of the limitations of current cancer treatments, particularly in solid tumors, where the immune system often struggles to maintain a prolonged and effective attack on the tumor.

Reference: Kole R. DeGolier et al, Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response, Nature Immunology (2025). DOI: 10.1038/s41590-024-02034-1

Love this? Share it and help us spark curiosity about science!

TweetShareSharePinShare

Recommended For You

Health and Medicine

Your Brain Keeps Growing New Neurons Even in Old Age

July 5, 2025
Health and Medicine

This Pig Kidney Survived in a Human Body for 61 Days and Changed Everything

July 4, 2025
Woman hand checking lumps on her breast for signs of breast cancer on white background. Healthcare concept. Cancer self check; healthy girl.
Health and Medicine

One Hormone Combo Raises Cancer Risk While Another May Lower It

July 4, 2025
Two-photon microscopy captures axonal segments in a living brain, enabling researchers to quantify structural changes in specialized areas under noninvasive low-intensity repetitive transcranial magnetic stimulation (rTMS). A zoomed-out survey of the brain area (A) shows complex networks of neurons, visible via fluorescent marker. Insets (B and C) show specialized axonal endings (termed "boutons") where synapses form. TB axon: "terminaux boutons" are short protrusions from the axon shaft typically connecting neurons in a local area. EPB axon: "en passant boutons" are small bead-like structures along axons typically connecting distal regions. Credit: B. Fulopova (Queen's University).
Health and Medicine

Magnetic Brain Pulses Awaken Lost Connections in Alzheimer’s

July 4, 2025
Health and Medicine

The Brain’s Sugar Secret Could Be the Key to Beating Alzheimer’s

July 4, 2025
Cytomegalovirus. Credit: CDC/Dr. Edwin P. Ewing, Jr. (PHIL #958), 1982.
Health and Medicine

The Secret Door That Lets a Silent Virus Harm Newborns

July 4, 2025
Health and Medicine

Your Gut Might Be Behind Your Binge Eating and Diet Struggles

July 4, 2025
Health and Medicine

What Are Memories Made Of If Even Neuroscientists Can’t Agree

July 4, 2025
Health and Medicine

The Weight Loss Medication That Might Stop Migraines

July 3, 2025
Next Post
Derivation of hPSC-derived vascular endothelial cells, smooth muscle cells, and pericytes. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-54917-4

How COVID-19 Impacts Blood Vessels

Cancer types and subtyping. Credit: Cancer Cell (2024). DOI: 10.1016/j.ccell.2024.12.002

New Tool Classifies Cancers with Unprecedented Accuracy

Credit: iStock

Nasal Swab Test Accurately Identifies Asthma Endotypes in Children

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Legal

  • About Us
  • Contact Us
  • Disclaimer
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

© 2025 Science News Today. All rights reserved.

No Result
View All Result
  • Biology
  • Physics
  • Chemistry
  • Astronomy
  • Health and Medicine
  • Psychology
  • Earth Sciences
  • Archaeology
  • Technology

© 2025 Science News Today. All rights reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.